4//SEC Filing
Dubovsky Filip 4
Accession 0001104659-24-062148
CIK 0001000694other
Filed
May 14, 8:00 PM ET
Accepted
May 15, 9:15 PM ET
Size
9.2 KB
Accession
0001104659-24-062148
Insider Transaction Report
Form 4
NOVAVAX INCNVAX
Dubovsky Filip
President, R&D
Transactions
- Exercise/Conversion
Common Stock
2024-05-14$6.97/sh+19,652$136,974→ 86,265 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-14−19,652→ 47,728 totalExercise: $6.97Exp: 2033-03-07→ Common Stock (19,652 underlying) - Sale
Common Stock
2024-05-14$13.90/sh−47,312$657,637→ 38,953 total
Footnotes (2)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $14.00, inclusive. The Reporting Person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Documents
Issuer
NOVAVAX INC
CIK 0001000694
Entity typeother
Related Parties
1- filerCIK 0001977361
Filing Metadata
- Form type
- 4
- Filed
- May 14, 8:00 PM ET
- Accepted
- May 15, 9:15 PM ET
- Size
- 9.2 KB